A spin immunoassay for diphenylhydantoinis reported, which appears to give an accurate and precise estimate of serum diphenylhydantoin concentrations, as judged by the disappearance of [14C]diphenylhydantoin from the serum of a rabbIt. The assay also appears to be a reliable technique for routine diphenylhydantoin determinations, as judged from our experience wIth 28 patients. Serum diphenyihydantoin concentrations in the range of 1.0-50.0 mg/liter are easily determined on a 50-M' sample. Except for primidone, no significant cross reactivity was observed with eight drugs that are commonly used in conjunction with diphenyihydantoin therapy. This fast, simple, and precise method therefore appears to be readily applicable to routine determination of dipl'fenylhydantoin.
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Addftlonal Keyphrases: gas chromatography #{149} radloimmunoassay #{149} electron spin resonance Radioimmunoassay represents a major step forward in the development of rapid, sensitive, and economical assays for dete*mination of serum drug concentrations.
Yet there remain two areas in which this assay could be improved.
The first is that frequently not only the parent compound but also its metabolites and congeners can bind to the antibody, so that the method may lack specificity. This is a problem with all immunoassays, which can only be resolved by a thorough study of a wide variety of antigens in a wide range of animals with the hope of developing more specific antibodies.
The second problem is that the radioimmunoassay requires that the free and the antibody-bound label somehow be physically separated. Although some ele-gant and reliable methods of doing this have been devised, they require an added two to three steps that may introduce error, entail added labor and cost, and are difficult to fully automate. These problems prompted us to examine an alternative detection system for the immunoassay, the spin-labeled immunoassay (1) (2) (3) (4) .
In this assay the rapidly rotating free spin-labeled drug gives three sharp peaks in the ESR' spectrometer. In contrast, when the drug becomes bound to the antibody, the peaks broaden out so that the maximum peak-height drops by a factor of 10g. Hence, when the drug binds to the antibody, the ESR spectrum essentially disappears. On the other hand, when unlabeled drug competitively displaces the spin-labeled drug from the antibody, the ESR spectrum reappears.
The height Of the observed peaks are, therefore, directly proportiOnal to the unlabeled drug concentration.
Since the ESR spectrometer only delebts th free drug, this assay does not require that the free and bound drug be physically separated.
This method was originally used to detect morphine congeners in urine (2) (3) (4) and, more recently, in serum (1) . It has been found to be quick (requiring only 2 mm of technician's time), simple, and sufficiently sensitive for many of the drugs routinely determined in the serum [minimum sensitivity, about 20-30 nmol (1) ].
In this work we have examined a new spin immunoassay for the determination of serum DPH and compared it to a standard gas-chromatographic method. Our results suggest that the spin immunoassay is sufficiently precise, accurate, and convenient to warrant its application in the routine clinical analysis of this drug in serum. Pa for 3 h) was added to a solution of 4 mg (0.09 rnmol) of sodium hydride (560 g/liter) in 20 ml of anhydrous methanol, and the mixture was stirred under nitrogen at room temperature for 15 h. Excess solid carbon dioxide was carefully added to quench the reaction and the mixture was evaporated under reduced pressure and maintained at 6.65 Pa for 2 h. The resulting solid was dissolved in 50 ml of dry benzene (stored over sodium), filtered, and the volume decreased under pressure to 10 ml. Petroleum ether was added dropwise to the hot benzene solutiOn until it became cloudy, and the mixture was allowed to cool. Three hundred milligrams of colorless crystals was collected (mp 149-150 #{176}C) and another 150 mg (mp 146-149 #{176}C) could be isolated from the mother liquor by evaporation of the solution and recrystallization from dichloromethane:petroleum ether. Calculated for C18H17N303: C 66.86%, H 5.30%, N 13.00%. Found: C 66.67%, H 5.34%, N 13.07%. hydrochloride and the resulting solution was stirred overnight. The reaction mixture was chromatographed on preparative chromatographic plates (silica gel GF), with 'concentrated ammonia:ethylacetate (1:50 by vol) as solvent. The yellow band (RF = 0.7) was scraped from the plate and the drug was eluted from the silica gel with the solvent used above (100 ml). The solvent was evaporated and the residue was dissolved in diethylether.
After filtration, the solvent was removed Under reduced pressure and the residue dried at 6.65 Pa for 1 h. A yellow glassy residue was obtained (75 mg) (mol wt 448.5; mass spectrum M = 448).
Preparation
of the conjugate with bovine serum albumin. A solution of 300 mg of 3-N-(methoxycarbi-'midomethyl)-diphenylhydantoin in 3 ml of dioxane (freshly opened bottle) was added, with constant stirring, to a solution of 300 mg of bovine serum albumin in 10 ml of water at 0 #{176}C and pH 0.5. The pH was maintained with normal sodium hydroxide by use of the "pH-stat" mode of a Radiometer Auto-Titrator. After 16 h the mixture was dialyzed against distilled water. A precipitate appeared.
It was removed by centrifugation (12 000 X g for 20 mm). The supernate was desalted on a Pharmacia K-26 column packed with G-25 (medium) Sephadex (Pharmacia Laboratories Inc., Piscataway, N.J. 08854) and lyophilized to yield 200 mg of conjugate with a hapten number of 53. The hapten number was determined by reference to a standard ultraviolet calibration curve, which was obtained by measuring the absorbances of known bovine serum albumin/DPH-derivative (N-3-carbamidinomethyl-DPH) mixtures at 280 nm (A) and 257 nm (A257) and plotting the ratio A0/A257
vs.the bovine serum albuminfDPH-derivative ratios.
Preparation of anti-DPH--y-globulin.
The conjugate was injected intramuscularly into a sheep at four-week intervals. For the initial injection, 10 mg of the conjugate was dissolved in 1 ml of saline (9 g of NaCI per liter) and emulsified in 3 ml of complete
Freund's adjuvant. The second injection was prepared identically in incomplete Freund's adjuvant. For the subsequent monthly injections, 2 mg of the conjugate was dissolved in 1 ml of saline and emulsified in 3 ml of incomplete Freund's adjuvant.
The antiserum was precipitated at 0 #{176}C by addition of an equal volume of saturated ammonium sulfate. The pellet obtained after centrifugation (12 000 g, 20 mm) was redissolved in borate buffer (0.4 mol/ liter, pH 8.0). After dialysis against 100 volumes of borate buffer (three changes), the binding site concentration and binding constant were determined by titration with DPH spin label. The binding site concentration was 1.9 X i0 mol/titer and the binding constant was 4.6 X 106 liter/mol for the antibodies used in this experiment.
The antibody was diluted with borate buffer to a binding-site concentration of 1.8X 10 mol/liter.
The spin label was weighed out and dissolved in a small amount of ethanol and diluted with distilled water to 1.58 X 10 mol/liter. The final alcohol concentration was about 50 mI/liter. The correct spin label concentration was established by calibrating the DPH spin label solution against a morphine spin 'label solution of known concentration (by weight) with use of the low-field ESR signal for comparison.
To prepare the "spin labeled-y-globulin," we combined 5 sl of the antibody with 5 il of the spin labeled DPH.
Ten microliters of the spin labeled-y-globulin reagent was added to 40 tl of serum containing the unknown concentration of DPH. Blank samples were obtained by adding the 10 d of antibody/spin labeled hapten complex to 40 Ml of pooled human serum. Standards were prepared by adding various amounts of sodium 5,5-diphenylhydantoin (Sigma Chemical Co., St. Louis, Mo. 63178) to the same pooled human serum. Incubation time for the spin-labeled DPHantibody complex with the DPH containing solution was 60-90 mm, as previously described (1) .
Binding of spin-labeled DPH to serum proteins. Binding of the N3 -substituted, spin-labeled DPH to serum proteins was assessed by adding an aliquot of the spin-labeled compound to human serum containing DPH (5,5'-diphenylhydantoin sodium, Sigma) at a final concentration of 10 g/ml and comparing the amplitude of the low-field signal in the presence of serum to the amplitude of this peak for the same concentration of spin-labeled DPH in water. The decreased signal observed in the presence of serum is due to the binding of the spin-labeled drug to the serum albumin and the resultant immobilization of the free-radical species (1). The ESR spectrometer settings for these studies were the same as for the serum DPH assay except that the receiver gain was 2.5 X 10g.
Metabolism of DPH in rabbits.
[4-'4C}-DPH (New England Nuclear, Boston, Mass. 02118; lot No. 648-298; spec. act., 5.21 Ci/mol) was dissolved in saline and diluted with 'unlabeled sodium DPH in a final concentration of 25 g/liter (5 mCi/liter). One hundred milligrams of this dosing solution was injected intravenously into the marginal ear vein of a 4-kg female New Zealand white rabbit, and blood samples were withdrawn at various times from the opposite ear vein. The serum was separated and immediately frozen for later analysis. Aliquots of serum (0.10 ml) were dissolved in 10 ml of "Aquasol" scintillator fluid (New England Nuclear) and counted in a Beckman LSC 1000 counter, (Beckman Instruments, Inc., Fullerton, Calif. 92634).
Thin-layer chromatography. Serum samples containing ['4C]-DPH were extracted with chloroform: methanol (9:1), evaporated under reduced pressure, and the residue was chromatographed on silica gel GF plates with chloroform:methanol (9:1) as the developing solvent. The plate was scanned in a scanner (Packard Instrument Co., Powners Grove, Ill. 60515, and then #{149}0.5-cm segments were scraped from it.
These scrapings were counted in 10 ml of "Aquasol." Ultrafiltration.
Triplicate 5-ml aliquots of fresh human sera to which DPH was added (10 g/ml, plus 
Determination of DPH by gas chromatography.
The concentration of DPH in serum was determined essentially by the method of Kupferburg (5) . In this method 5-(4'-methylphenyl)-5-phenylhydantoin was added to the serum (1 ml) as an internal standard to give a final concentration of g/ml. This was followed by the addition of potassium phosphate buffer (1 ml, 0.25 mol/liter, pH 7.4). The drug was extracted into 6 ml of ethylene dichloride. Hexane (5 ml) was added and the organic phase extracted with K3PO4 (0.2 mol/liter, 4.5 ml). Of the aqueous phase, 3.5 ml was acidified with HC1 (5 mol/liter, 0.3 ml) and finally extracted into 10 ml of ethylene dichioride. The extract was dried in a stream of nitrogen and redissolved in 50 Ml of a 0.1 mol/liter solution of trimethylanilinium hydroxide in methanol. The mixture was then injected into a Perkin-Elmer Model 881 gas chromatograph (Perkin-Elmer Corp., Norwalk, Conn. 06856), with a six-foot glass column packed with 3% OV-1
Gas Chrom Q (60-80 mesh; Applied Science Labora- 
Results
For determination of DPH in serum we prepared a standard curve (Figure 1 ) with use of sera supplemented with DPH in various concentrations. Figure 1 shows the peak-to-peak amplitude of the low field nitroxide triplet peak (after subtraction of the non-DPH-containing serum blank) for various DPH concentrations between 1.0-50.0 g of DPH per milliliter. A new standard curve was prepared daily for routine DPH analysis.
To establish the reliability and validity of this assay for the determination of serum DPH, we gave a female rabbit [4-'4C]5,5-diphenylhydantoin (25 mg/ kg orally), and serum DPH concentrations were determined by liquid scintillation counting, the spin immunoassay technique, and gas-chromatography at several time intervals from 20 mm to 24 h after administration ( Figure 2 ). The DPH dosage was selected to produce serum DPH concentrations similar to those produced in man by therapeutic doses of DPH (6, 7) . The distribution of DPH was apparently complete 20 mm after the intravenous administration. Between 1.0 and 40 g of DPH per milliliter of serum, the agreement between the '4C activity, the gas-chromatographic determination, and the spin immunoassay was quite good; the half-life for this linear phase of drug disappearance was 4.0 h. At serum concentrations of DPH greater than 40 g/ml the spin' immunoassay tended to give slightly higher values than did measurement of '4C-activity or the gaschromatographic determination. This discrepancy disappeared when the samples of higher concentration (>40 mg/liter) were diluted with an equal volume of non-DPH-containing serum and then assayed for '4C-activity and by spin immunoassay. These data for the spin immunoassay determination also indicate a high degree of intra-assay precision on triplicate determinations.
Thin-layer chromatography of a chloroform:methanol extract of rabbit serum obtained 6 h after DPH administration indicated that 96% of the 'C activity was present in the serum as unmetabolized DPH.
The residual 4% of the '4C activity was in a compound that corresponded to an authentic standard of p -hydroxydiphenylhydantoin, indicating that only a small fraction of the serum concentration of '4C activity was present as the hydroxylated DPH metabolite. Thus, the 14C activity evidently provided a good estimate of the true concentration of DPH in serum. We checked the possibility of cross reactivity in the spin immunoassay of several compounds that are frequently used with DPH therapy. Human serum containing 10 g of DPH per milliliter (36.5 Mmol) was used as the reference standard.
To this serum was added each of the indicated compounds (Table  1) at an equimolar concentration (36.5 smol), and at 10 (365 Mmol) and 1Q0-fold excess of the DPH (3.65 mmol). The serum sznple was then spin-immunoassayed and the results were compared to a serum sample containing 1Og (36.5 Mrnol) of DPH per milliliter. Table 1 shows the percent response for each compound at each concentration studied as compared to 10 g of DPH per milliliter (100% response). Of'the therapeutic compounds, only primidone and the highest phenobarbital concentration showed significant binding to the DPH-antibody.
Because the phenobarbital concentration that gave cross reactivity in the assay is far in excess of that which is found in clinical situations (8) , it would be very unlikely that this false-positive reaction would be encountered. bvalues are percent response as compared to a solution containing only DPH (10 pg/mi).
Significant cross reactivity.
"ND, not determined, owing to insolubility. which has a therapeutic range of 5-15 g/ml (24-72 iimol) (9), would probably lead to an erroneously high value for DPH if both DPH and primidone were present in serum at roughly equal concentrations.
Since antibodies produced in different animal species are known to have different reactivities toward the same compound, the possibility of utilizing a different antibody source to circumvent this problem is currently being investigated.
The marked cross reactivity of the p-hydroxydiphenylhydantoin indicates that hydroxylation of the pa'o position on one of the phenyl rings of DPH does not significantly alter binding by the DPH-specific antibody. The cross reactivity of this DPH metabolite would not greatly affect the accuracy of the assay, however, because it is rapidly cleared by the kidneys and thus does not constitute a significant proportion of the total DPH in the serum. As indicated in the previously discussed rabbit study, only 4% of the total DPH was present in the serum as this compound; thus, its contribution to the total drug concentration in serum would be negligible.
To establish the reliability of this assay in the clinical situation, we obtained serum from 28 patients chosen without conscious bias, who were receiving DPH for seizure control, and simultaneously examined these sera by the spin immunoassay and gaschromatography.
As Figure 3 shows, the two methods agreed very well (r = 0.97, P < 0.001). Furthermore, the slope of the regression line was not significantly different from 1.0 (slope ±1 SD = 0.94 ± 0.04), indicating that the spin immunoassay measures serum DPH as precisely as does gas-chromatography.
Addition of spin-labeled drug without antibody to human serum results in a decreased peak amplitude as compared to spin-labeled drug in water, a decrease attributable to binding of the spin-labeled drug to serum proteins (Figure 4 ). In our study on morphine (1) we found that the decreased ESR signal agreed well with ultrafiltration data. On the other hand, for DPH both ultrafiltration and equilibrium dialysis gave a value of protein binding of 88% (Table 2) , in agreement with previous workers (10) . The spin-labeled DPH gave a markedly smaller percentage of binding to protein (61%). This difference in binding can be explained by the charge characteristic of the two spin-labeled haptens. In the case of spin-labeled morphine the charge of the molecule is essentially unaltered when compared with morphine. Spin-labeled DPH has a positive charge in the amidine linkage, which is nonexistent in DPH. Therefore, the spin-labeled DPH is more hydrophilic and binds less to the hydrophobic binding sites occupied by DPH.
Discussion
These studies indicate that the technique of spin immunoassay is readily applicable to the determination of serum diphenyihydantoin, and offers several advantages over its assay by either gas chromatography or radioimmunoassay.
Perhaps the single most attractive advantage of this method is the speed and simplicity of operation-the entire assay requires only the mixing of two solutions and then, after an equilibration period during which other samples can be prepared, the concentration can be directly determined by a 2-4 mm scan on the ESR spectrometer. In contrast, with radioimmunoassays it is necessary to include a step for separating the free label from that bound to antibody. If only for this reason, the spin immunoassay is faster, simpler, and less prone to errors resulting from multiple manipulations.
The sensitivity required for routine clinical monitoring of serum DPH (1-50 ig DPH per milliliter) is 100-fold greater than the lowest concentration that can be measured by this technique (1) . Therefore, this technique is readily adaptable for long-term monitoring of DPH disappearance in man or in laboratory animals.
Finally, the mechanical configuration of the microwave cavity in the ESR spectrometer should readily facilitate the complete automation of this technique.
A quartz solution-cell can be easily incorporated into a flow-through system, and serve as the detector unit in any one of a number of commercially available automated mixing and incubation flow systems.
